

CORRECTION

Open Access

A biregional survey and review of first-line treatment failure and second-line pediatric antiretroviral access and use in Asia and southern Africa

for TREAT Asia Pediatric HIV Observational Database (TApHOD)^{1*} and for The International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group²

Correction

The article published in [1], contains incorrect data in Table 1 regarding the nationally recommended paediatric second-line ART regimen after NNRTI failure in India. This has been corrected. The editors and authors

regret the inconvenience caused to readers by the error in the original paper.

Author details

¹TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
²Institute of Social and Preventive Medicine, University of Bern, Bern,

Table 1 First- and second-line antiretroviral therapy regimens in use in TREAT Asia and IeDEA Southern Africa

Site	Country	Nationally recommended paediatric first-line ART regimen*	Nationally recommended paediatric second-line ART regimen after NNRTI	Most commonly used second-line regimen in current site cohort
TREAT Asia				
National Center for HIV, AIDS, Dermatology, and Sexually Transmitted Infections	Cambodia	d4T or AZT+3TC+NVP or EFV If NNRTI exposure: d4T+3TC+LPV/r	ABC+ ddi+LPV/r	ABC+3TC+LPV/r
Beijing Ditan Hospital	China	d4T or AZT+3TC+NVP or EFV If NNRTI exposure: AZT+3TC+LPV/r	ABC+3TC+AZT+LPV/r	ABC+3TC+AZT+LPV/r
YRG Centre for AIDS Research and Education	India	d4T or AZT+3TC+NVP or EFV	ABC+ddi+3TC+LPV/r	TDF or ddi+3TC or FTC+LPV/r
Cipto Mangunkusumo Hospital	Indonesia	d4T or AZT+3TC+NVP or EFV	ddi+3TC+LPV/r	ddi+3TC+LPV/r
Hospital Kuala Lumpur	Malaysia	<3yr: AZT+3TC or ddi+NVP ≥3yr: AZT+3TC or ddi+EFV	2 new NRTI+LPV/r	d4T+3TC+LPV/r
Hospital Likas	Malaysia	<3yr: AZT+3TC or ddi+NVP ≥3yr: AZT+3TC or ddi+EFV	2 new NRTI+LPV/r	d4T+ddi+LPV/r
Hospital Penang	Malaysia	<3yr: AZT+3TC or ddi+NVP ≥3yr: AZT+3TC or ddi+EFV	2 new NRTI+LPV/r	-

* Correspondence: annette.sohn@treatasia.org

¹TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand
Full list of author information is available at the end of the article

Table 1 First- and second-line antiretroviral therapy regimens in use in TREAT Asia and leDEA Southern Africa (Continued)

Hospital Raja Perempuan Zainab	Malaysia	<3yr: AZT+3TC or ddi+NVP ≥3yr: AZT+3TC or ddi+EFV	2 new NRTI+LPV/r	d4T+ddi+LPV/r
Chiang Mai University Medical Centre	Thailand	d4T or AZT+3TC+NVP or EFV	ddi+ABC or 3TC+PI/r	AZT+3TC+LPV/r
Chiang Rai Regional Hospital	Thailand	d4T or AZT+3TC+NVP or EFV	ddi+ABC or 3TC+PI/r	AZT+3TC+LPV/r
HIV-NAT	Thailand	d4T or AZT+3TC+NVP or EFV	ddi+ABC or 3TC+PI/r	AZT+3TC+LPV/r
Khon Kaen University Medical Centre	Thailand	d4T or AZT+3TC+NVP or EFV	ddi+ABC or 3TC+PI/r	AZT+ddi+LPV/r
Siriraj Hospital	Thailand	d4T or AZT+3TC+NVP or EFV	ddi+ABC or 3TC+PI/r	AZT+ddi+LPV/r
Children's Hospital 1	Vietnam	d4T+3TC+NVP	ABC+ddi+LPV/r	-
Children's Hospital 2	Vietnam	d4T+3TC+NVP	ABC+ddi+LPV/r	ABC+ddi+LPV/r
National Hospital of Paediatrics	Vietnam	d4T+3TC+NVP	ABC+ddi+LPV/r	ABC+ddi+LPV/r
leDEA Southern Africa				
Lighthouse Clinic	Malawi	d4T+3TC+NVP	ABC+ddi+LPV/r	AZT+3TC+LPV/r
Paediatric Day Hospital, Maputo	Mozambique	d4T or AZT+3TC+NVP or EFV If NNRTI exposure: d4T or AZT+3TC+LPV/r	ABC+ddi+LPV/r	None
Rahima Moosa Mother and Child Hospital	South Africa	<3yr/10kg: d4T+3TC+LPV/r >3yr/10kg: d4T+3TC+EFV	AZT+ddi+LPV/r	ABC+3TC+LPV/r
Gugulethu Community Health Centre	South Africa	<3yr/10kg: d4T+3TC+LPV/r >3yr/10kg: d4T+3TC+EFV	AZT+ddi+LPV/r	AZT+ddi+EFV or LPV/r ABC +3TC+LPV/r
Harriet Shezi Clinic	South Africa	<3yr/10kg: d4T+3TC+LPV/r >3yr/10kg: d4T+3TC+EFV	AZT+ddi+LPV/r	AZT+ddi+LPV/r
Khayelitsha Community Health Centre	South Africa	<3yr/10kg: d4T+3TC+LPV/r >3yr/10kg: d4T+3TC+EFV	AZT+ddi+LPV/r	AZT+ddi+LPV/r
McCord Hospital	South Africa	<3yr/10kg: d4T+3TC+LPV/r >3yr/10kg: d4T+3TC+EFV	AZT+ddi+LPV/r	AZT+ddi+LPV/r
Red Cross Children's Hospital	South Africa	<3yr/10kg: d4T+3TC+LPV/r >3yr/10kg: d4T+3TC+EFV	AZT+ddi+LPV/r	AZT+ddi+EFV
Tygerberg Hospital	South Africa	<3yr/10kg: d4T+3TC+LPV/r >3yr/10kg: d4T+3TC+EFV	AZT+ddi+LPV/r	AZT+ddi+LPV/r
Newlands Clinic	Zimbabwe	AZT+3TC+NVP	ddi+3TC+LPV/r	d4T+3TC+NVP

*Content reflects current recommendations at the time of the survey. WHO first-line regimen recommendations at the time of the survey included two NRTIs with one NNRTI or two NRTIs with one PI/r if the infant had previous NNRTI exposure [10,17]; second-line regimen recommendations after NNRTI failure included two NRTIs with one PI/r or unboosted nelfinavir in limited circumstances.

d4T - stavudine; AZT - zidovudine; 3TC - lamivudine; NVP - nevirapine; EFV - efavirenz; ABC - abacavir; ddi - didanosine; LPV/r - ritonavir-boosted lopinavir; TDF - tenofovir; FTC - emtricitabine; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-nucleoside reverse transcriptase inhibitor.

Switzerland and the School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Received: 28 March 2011 Accepted: 8 April 2011 Published: 8 April 2011

Reference

1. TREAT Asia Pediatric HIV Observational Database (TApHOD), and The International Epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa Paediatric Group: A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. *J Int AIDS Soc* 2011, **14**(1):7.

doi:10.1186/1758-2652-14-17

Cite this article as: and : A biregional survey and review of first-line treatment failure and second-line pediatric antiretroviral access and use in Asia and southern Africa. *Journal of the International AIDS Society* 2011 **14**:17.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

